An Update of Safety and Efficacy Results oiii Phase 1 Dose-Escalation and Expansion Study of Vodobatinib, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI), in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph plus ALL) Failing Prior TKI Therapies

被引：3

作者：

Cortes, Jorge E. ^{[1
]}

Saikia, Tapan ^{[2
]}

Kim, Dong-Wook ^{[3
,4
]}

Alvarado, Yesid ^{[5
]}

Nicolini, Franck E. ^{[6
]}

Rathnam, Krishnakumar ^{[7
]}

Khattry, Navin ^{[8
]}

Apperley, Jane F. ^{[9
]}

Deininger, Michael W. ^{[10
]}

de Lavallade, Hugues ^{[11
]}

Charbonnier, Aude ^{[12
]}

Granacher, Nikki ^{[13
]}

Gambacorti-Passerini, Carlo ^{[14
]}

Lucchesi, Alessandro ^{[15
]}

Mauro, Michael J. ^{[16
]}

Vandenberghe, Peter ^{[17
]}

Verhoef, Gregor ^{[17
]}

Whiteley, Andrew R. ^{[18
]}

Nag, Arijit ^{[19
]}

Radhakrishnan, Vivek S. ^{[19
]}

Apte, Shashikant ^{[20
]}

Yao, Siu-Long ^{[21
]}

Inamdar, Sandeep ^{[22
]}

Sreenivasan, Jayasree ^{[22
]}

Dillu, Ruchika Irene ^{[22
]}

Chimote, Geetanjali ^{[22
]}

机构：

[1] Augusta Univ, Georgia Canc Ctr, Augusta, GA USA

[2] Prince Aly Khan Hosp, Mumbai, Maharashtra, India

[3] Catholic Univ Korea, Seoul St Marys Hosp, Catholic Hematol Hosp, Coll Med,Dept Hematol, Seoul, South Korea

[4] Catholic Univ Korea, Seoul St Marys Hosp, Catholic Hematol Hosp, Coll Med, Seoul, South Korea

[5] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

[6] Ctr Leon Berard, Hematol Dept, Lyon, France

[7] Meenakshi Mission Hosp & Res Ctr, Lake Area, Melur Main Rd, Madurai, Tamil Nadu, India

[8] Tata Mem Hosp, ACTREC, Dept Med Oncol, BMT Unit, Navi Mumbai, India

[9] Imperial Coll, Hammersmith Hosp, Ctr Haematol, Dept Med, London, England

[10] Univ Utah, Huntsman Canc Inst, Div Hematol & Hematol Malignancies, Salt Lake City, UT USA

[11] Kings Coll Hosp London, NHS Fdn Trust, Dept Haematol Med, London, England

[12] Inst Paoli Calmettes, Dept Hematol, Marseille, France

[13] Ziekenhuis Netwerk Antwerpen, Antwerp, Belgium

[14] Univ Milano Bicocca, Dept Med & Surg, Monza, Italy

[15] Ist Sci Romagnolo Studio & Cura Tumori IRST IRCCS, Hematol Unit, Meldola, FC, Italy

[16] Mem Sloan Kettering Canc Ctr, Myeloproliferat Neoplasms Program, Leukemia Serv, 1275 York Ave, New York, NY 10021 USA

[17] UZ Leuven, Dept Hematol, Leuven, Belgium

[18] Baylor Univ, Med Ctr, Dallas, TX USA

[19] Tata Med Ctr, Clin Hematol Oncol & HCT, Kolkata, India

[20] Punes Sahyadri Hosp, Pune, Maharashtra, India

[21] Sun Pharmaceut Ind Inc, Princeton, NJ USA

[22] Sun Pharma Adv Res Co Ltd, Mumbai, Maharashtra, India

来源：

BLOOD | 2021年 / 138卷

关键词：

D O I：

10.1182/blood-2021-152548

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

309

引用

页数：6

共 50 条

[31] Multivariate Analyses of the Clinical and Molecular Parameters Associated with Efficacy and Safety in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph plus ALL) Treated with Ponatinib in the PACE Trial
Mauro, Michael J.
Cortes, Jorge E.
Kim, Dong-Wook
Pinilla-Ibarz, Javier
le Coutre, Philipp
Paquette, Ronald
Chuah, Charles
Nicolini, Franck E.
Apperley, Jane
Khoury, H. Jean
Talpaz, Moshe
DiPersio, John F.
DeAngelo, Daniel J.
Abruzzese, Elisabetta
Rea, Delphine
Baccarani, Michele
Muller, Martin C.
Gambacorti-Passerini, Carlo
Wong, Stephane
Dorer, David J.
Knickerbocker, Ronald Keith
Rivera, Victor M.
Clackson, Tim
Turner, Christopher D.
Haluska, Frank G.
Guilhot, Francois
Deininger, Michael W.
Hochhaus, Andreas
Hughes, Timothy
Goldman, John M.
Shah, Neil
Kantarjian, Hagop M.
BLOOD, 2012, 120 (21)
[32] Next Generation Sequencing-Based BCR-ABL1 Kinase Domain Mutation Screening in De Novo and Tyrosine Kinase Inhibitor-Resistant Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of a Prospective Study
Soverini, Simona
Bavaro, Luana
Martelli, Margherita
De Benedittis, Caterina
Papayannidis, Cristina
Percesepe, Antonio
Laginestra, Maria Antonella
Sica, Simona
Sora, Federica
Albano, Francesco
Pagano, Livio
Criscuolo, Marianna
Galimberti, Sara
Salvucci, Marzia
Annunziata, Mario
Marconi, Giovanni
Curti, Antonio
Russo, Sabina
Imovilli, Annalisa
Mannina, Daniele
Ferrero, Dario
Stulle, Manuela
Basilico, Claudia
Abruzzese, Elisabetta
Mignone, Flavio
Pileri, Stefano A.
Martinelli, Giovanni
Cavo, Michele
BLOOD, 2018, 132
[33] The safety and efficacy of dasatinib plus nivolumab in patients with previously treated chronic myeloid leukemia: results from a phase 1b dose-escalation study
Martinez-Lopez, Joaquin
Mustjoki, Satu
Porkka, Kimmo
Klisovic, Rebecca B.
Wolf, Dominik
Busque, Lambert
Hernandez-Boluda, Juan Carlos
Swanink, Rene
Martin Regueira, Patricia
Lipton, Jeffrey H.
LEUKEMIA & LYMPHOMA, 2021, 62 (08) : 2040 - 2043
[34] Olverembatinib (HQP1351) Combined with Chemotherapy Is an Effective and Safe Treatment in Patients with Philadelphia Chromosome-Positive (Ph plus ) Acute Lymphoblastic Leukemia (ALL) and Chronic Myeloid Leukemia in Lymphoid Blast Phase (CML-LBP) That Failed TKI-Based Regimens
Li, Zongru
Ting, Zhao
Hu, Lijuan
Duan, Wenbing
Jiang, Qian
BLOOD, 2023, 142
[35] Preliminary activity of AMN107, a novel potent oral selective Bcr-Abl tyrosine kinase inhibitor, in newly diagnosed Philadelphia chromosome (Ph)-positive chronic phase chronic myelogenous leukemia (CML-CP).
Jabbour, E.
Giles, F.
Cortes, J.
O'Brien, S.
Ravandi, F.
Borthakur, G.
Garcia-Manero, G.
Letvak, L.
Salvado, A.
Kantarjian, H.
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 358S - 358S
[36] Trial in Progress: A Multicenter, OpenLabel, Phase Ib/II Study to Determine the Dose and Safety of Asciminib in Pediatric Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase Treated with ≥1 Prior Tyrosine Kinase Inhibitor
Hijiya, Nobuko
Kapoor, Shruti
Descamps, Laurence
Bayar, Mohamed Amine
Ramscar, Nicholas
BLOOD, 2021, 138
[37] Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant BCR-ABL1 T315I-Mutated Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP)
Qian, Jiang
Shi, Dayu
Li, Zongru
Hou, Yue
Hu, Yu
Li, Weiming
Liu, Xiaoli
Xu, Na
Song, Yongping
Zhang, Gongli
Meng, Li
Hong, Zhenya
Liu, Bingcheng
Li, Yan
Chen, Suning
Xue, Mengxing
Zhu, Huanling
Li, He
Du, Xin
Lou, Jin
Zhang, Xiaohan
Liang, Yang
Dai, Yujun
Chen, Zi
Niu, Qian
Men, Lichuang
Yang, Dajun
Zhai, Yifan
Huang, Xiaojun
BLOOD, 2021, 138
[38] Preliminary activity of nilotinib (AMN107), a novel selective potent oral Bcr-Abl tyrosine kinase inhibitor, in newly diagnosed Philadelphia chromosome (Ph)-positive chronic phase chronic myelogenous leukemia (CML-CP).
Jabbour, Elias
Cortes, Jorge
Giles, Francis
O'Brien, Susan
Letvak, Laurie
Kantarjian, Hagop
BLOOD, 2006, 108 (11) : 616A - 616A
[39] Trial in Progress: Phase 1b Bridging Study of the Pharmacokinetics (PK), Safety, and Efficacy of Orally Administered Olverembatinib (HQP1351) in Patients with Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
Jabbour, Elias J.
Kantarjian, Hagop
Issa, Ghayas C.
Beck, Joseph Thaddeus
Klisovic, Rebecca B.
Mukherjee, Sudipto
Oehler, Vivian G.
Chen, Zi
Lu, Ming
Fu, Tommy
Jiang, Lixin
Zhai, Yifan
Yang, Dajun
BLOOD, 2021, 138
[40] ASC2ESCALATE Trial in Progress: A Phase 2 Single-Arm Dose Escalation Study of Asciminib Monotherapy in Patients With Chronic Myeloid Leukemia in Chronic Phase (CMLCP) Previously Treated With 1 Prior Tyrosine Kinase Inhibitor (TKI)
Sasaki, Koji
Mauro, Michael J.
Levy, Moshe Y.
Atallah, Ehab L.
Koller, Paul
Maegawa, Rodrigo
Damon, Andrea
Kumar, Julie
Khan, Mahmudul
Cortes, Jorge E.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S299 - S299

← 1 2 3 4 5 →